141505-33-1
141505-33-1 structure
- Name: Levosimendan
- Chemical Name: levosimendan
- CAS Number: 141505-33-1
- Molecular Formula: C14H12N6O
- Molecular Weight: 280.285
- Catalog: API Circulatory system medication Anti-congestive heart failure medicine
- Create Date: 2018-06-15 12:11:54
- Modify Date: 2024-01-02 12:09:32
-
Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3].
| Name | levosimendan |
|---|---|
| Synonyms |
Levosimedan
Mesoxalonitrile (-)-[p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone ({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)malononitrile ({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl]phenyl}hydrazono)malononitrile (R)-[[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile Propanedinitrile, 2-[2-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]- Levosimendan (R)-(-)-2-[4-(4-methyl-6-oxo-1,4,5,6,-tetrahydropyridazin-3-yl)phenylhydrazono]propanedinitrile MFCD00867135 Simdax (2-{4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazinyliden)propandinitril 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile (R)-Simendan |
| Description | Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Melting Point | 216-219ºC (dec.) |
| Molecular Formula | C14H12N6O |
| Molecular Weight | 280.285 |
| Exact Mass | 280.107269 |
| PSA | 113.43000 |
| LogP | 0.59 |
| Index of Refraction | 1.673 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H312-H332 |
| Precautionary Statements | P280 |
| Hazard Codes | Xn |
| Risk Phrases | R20/21/22 |
| Safety Phrases | S36/S37 |
| RIDADR | NONH for all modes of transport |
| RTECS | TY1570210 |
|
~%
141505-33-1 |
| Literature: WO2011/7123 A1, ; Page/Page column 11-12 ; |
|
~%
141505-33-1 |
| Literature: WO2011/7123 A1, ; |
|
~%
141505-33-1 |
| Literature: WO2011/7123 A1, ; |
|
~%
141505-33-1 |
| Literature: WO2011/7123 A1, ; |
| Precursor 4 | |
|---|---|
| DownStream 0 | |